Figure 1.
In vitro and in vivo antiproliferative effects of copanlisib-containing combinations in lymphoma models. (A) In vitro combination in B-cell lymphoma cell lines derived from MCL, MZL, and CLL. (B) In vitro combination in T-cell lymphomas cell lines derived from ALCL, PTCL, and CTCL. (C) Antitumor in vivo activity of copanlisib in combination with venetoclax or lenalidomide in the MZL SSK41 model. Mice were treated with vehicle (IV), copanlisib (14 mg kg IV, 2 days on/5 days off), venetoclax (200 mg/kg, postoperatively, once per day), lenalidomide (50 mg/kg, postoperatively, once per day), copanlisib plus venetoclax (same doses as the single agents), or copanlisib plus lenalidomide (same doses as the single agents). Lines show median values per time point with the corresponding upper interquartile range. The y-axis indicates the tumor volume in millimeters cubed; the x-axis, days of treatment (P values shown in supplemental Table 4).

In vitro and in vivo antiproliferative effects of copanlisib-containing combinations in lymphoma models. (A) In vitro combination in B-cell lymphoma cell lines derived from MCL, MZL, and CLL. (B) In vitro combination in T-cell lymphomas cell lines derived from ALCL, PTCL, and CTCL. (C) Antitumor in vivo activity of copanlisib in combination with venetoclax or lenalidomide in the MZL SSK41 model. Mice were treated with vehicle (IV), copanlisib (14 mg kg IV, 2 days on/5 days off), venetoclax (200 mg/kg, postoperatively, once per day), lenalidomide (50 mg/kg, postoperatively, once per day), copanlisib plus venetoclax (same doses as the single agents), or copanlisib plus lenalidomide (same doses as the single agents). Lines show median values per time point with the corresponding upper interquartile range. The y-axis indicates the tumor volume in millimeters cubed; the x-axis, days of treatment (P values shown in supplemental Table 4).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal